鞘内佐剂用于剖宫产围术期管理的疗效与安全性:系统综述与网状Meta分析
结果显示,各佐剂均未显著降低24小时疼痛强度,但吗啡单用或联合哌替啶、新斯的明、肾上腺素或纳布啡可显著延长有效镇痛时间并减少阿片类药物用量;右美托咪定和吗啡显著延长运动阻滞时间;总体证据强度极低至低。
要点
- 吗啡单用或联合其他佐剂可显著延长有效镇痛时间并减少术后阿片用量
- 右美托咪定和吗啡显著延长运动阻滞持续时间
- 各鞘内佐剂均未显著增加严重不良事件发生率
核心结论
- 各鞘内佐剂均未显著降低剖宫产术后24小时疼痛强度,但多种佐剂可显著延长有效镇痛并减少阿片消耗,且未显著增加严重不良事件。
主要发现
- 丁丙诺啡和二氢吗啡酮在降低24小时疼痛强度方面排名最高,但差异无统计学意义。
- 吗啡单用或联合哌替啶、新斯的明、肾上腺素或纳布啡可显著延长有效镇痛时间并减少阿片类药物用量。
- 右美托咪定和吗啡显著延长运动阻滞持续时间。
- 鞘内佐剂总体安全性可接受,未显著增加严重不良事件。
关键数值与推荐
- 纳入标准为在单次腰麻下接受剖宫产、长效局麻药中加入任何鞘内药物或安慰剂的单盲或双盲、平行组随机对照试验。
- 排除交叉设计、非随机、上下法剂量探索及所有研究组比较相同药物的试验。
- 总体证据强度为极低至低。
临床怎么用
- 剖宫产单次腰麻时可根据需要选择吗啡单用或联合哌替啶、新斯的明、肾上腺素或纳布啡以延长镇痛并减少阿片用量。
- 选用右美托咪定或吗啡时需注意运动阻滞时间延长的可能。
局限性
- 总体证据强度为极低至低。
- 未来需大规模随机对照试验提供更可靠证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cesarean section (CS) rates have increased globally, necessitating effective anesthesia management. Single-shot spinal anesthesia has limitations due to its duration and the dose-limiting adverse effects of local anesthetics. OBJECTIVES: To evaluate the effectiveness and safety of intrathecal adjuvants combined with local anesthetics in the perioperative management of CS pain. DESIGN: Systematic review with network meta-analysis. DATA SOURCES: PubMed, Cochrane Library for Clinical Trials, and Embase. ELIGIBILITY CRITERIA: We included women undergoing CS under single-shot spinal anesthesia with any intrathecal drug or placebo added to a long-acting local anesthetic. We selected single- or double-blind, parallel-group, randomized controlled trials (RCTs) reported in English. We excluded crossover, non-randomized, up-and-down dose-finding studies and clinical trials comparing the same drugs in all study arms. RESULTS: We included 166 RCTs with 14 925 patients assigned to 32 interventions. Buprenorphine and diamorphine were the highest-ranked treatments for reducing pain intensity at 24 hours, though not statistically significant. Morphine alone or in combination with meperidine, neostigmine, epinephrine, or nalbuphine significantly increased the duration of effective analgesia and reduced opioid consumption. Dexmedetomidine and morphine significantly prolonged the motor block duration. The safety profile of intrathecal adjuvants was generally adequate. CONCLUSIONS: While the strength of evidence, overall, was very low to low, our study suggests that while none of the interventions significantly reduced pain intensity at 24 hours, several significantly prolonged effective analgesia and reduced postoperative opioid consumption. Dexmedetomidine and morphine prolonged the duration of motor block. None of the intrathecal adjuvants evaluated significantly increased the occurrence of severe adverse events. Future large-scale RCTs are essential to provide more robust evidence. PROSPERO REGISTRATION NUMBER: CRD42024479424.
引用
- Ollosu M, Tripodi VF, Bonu A, et al. Efficacy and safety of intrathecal adjuvants for perioperative management of cesarean delivery: a systematic review and network meta-analysis of randomized controlled trials. Reg Anesth Pain Med. 2026. PMID: 40147822. doi:10.1136/rapm-2024-106345
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。